Leveraging Large Language Models (LLMs) to Streamline Regulatory Submissions and Accelerate Clinical Trial Approvals

This presentation will explore the innovative application of LLMs in optimising the regulatory submission process for new medical devices and drugs, as well as expediting clinical trial applications. By harnessing the power of advanced natural language processing, LLMs offer a transformative approach to analysing and interrogating submissions to National Regulatory Agencies (NRAs). We will demonstrate how LLMs can be deployed to rapidly review extensive documentation, extract key information, and identify potential gaps or inconsistencies in regulatory submissions. This capability significantly reduces the time and resources required for manual review, allowing regulatory professionals to focus on critical decision-making tasks. Furthermore, we will discuss the application of LLMs in fast-tracking clinical trial applications. By analysing historical approval data, regulatory guidelines, and trial protocols, these models can provide insights to optimize study designs, predict potential challenges, and suggest improvements to increase the likelihood of approval. The presentation will cover:

• Implementation strategies for integrating LLMs into existing regulatory workflows
• Case studies highlighting efficiency gains in submission review and clinical trial approval processes
• Potential challenges and ethical considerations in adopting AI-driven approaches in regulatory affairs

Future perspectives on the evolving role of LLMs in streamlining drug and device development pipelines By leveraging LLMs, regulatory agencies and pharmaceutical companies can potentially accelerate the approval process for new medical products, ultimately benefiting patients by bringing innovative treatments to market more rapidly while maintaining rigorous safety and efficacy standards.